IP Library Granted Patent US 11,179,343
Granted Patent B2
US 11,179,343 · App. 16/893,986 · Granted Nov 23, 2021

Vaccine delivery systems using yeast cell wall particles

Inventor: Thomas E. Wagner (Greenville, SC)
Assignee: Orbis Health Solutions, LLC
A61K9/5068A61K9/19A61K31/70A61K31/7088A61K39/0011A61K39/39C12N1/16A61K2039/5154A61K2039/55561A61K2039/55572A61K2039/55588A61K2039/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,179,343
App. No.
16/893,986
Granted
Nov 23, 2021
Kind
B2
Abstract

The present invention generally relates to compositions and methods for delivering a vaccine. The compositions and methods disclosed herein are particularly useful in making prophylactic and therapeutic vaccines.

Claims (11)

1. A composition comprising (i) a yeast cell wall particle (YCWP); (ii) a silicate; and (iii) an exogenous biological material loaded within the YCWP, wherein the YCWP is modified by capping with the silicate, wherein the biological material comprises a protein or a fragment thereof, nucleic acid, carbohydrate, antigen or a combination thereof, and wherein the biological material is not a tumor lysate, viral antigen, or bacterial antigen.

2. The composition of claim 1 , wherein the biological material is an antigen that induces an immune response upon administration to a subject.

3. The composition of claim 2 , wherein the antigen is selected from the group consisting of a protein, a peptide, an epitope, a nucleic acid, and an immunogenic fragment or a subunit thereof.

4. The composition of claim 1 , wherein the YCWP loaded with the biological material is further incubated with an isolated dendritic cell prior to administration.

5. The composition of claim 4 , wherein the dendritic cell is an immature cell that has been isolated for no more than 8 days prior to incubation.

6. A method for efficiently delivering a vaccine to a subject comprising administering a composition of claim 1 .

7. A method for treating cancer, comprising administering the composition of claim 1 to a subject.

8. A composition comprising a yeast cell wall particle (YCWP), a silicate, and an exogenous biological material loaded within the YCWP, wherein the biological material comprises a protein or a fragment thereof, nucleic acid, carbohydrate, or a combination thereof, and wherein the biological material is not a tumor lysate, viral antigen, or bacterial antigen, wherein the YCWP is modified by coating with the silicate, wherein the silicate comprises an organic moiety attached to each of the four oxygen compounds of an orthosilicate.

9. The composition of claim 8 , wherein the silicate is tetraethylorthosilicate, tetramethylorthosilicate, tetrapropylorthosilicate, or tetrabutylorthosilicate.

10. The composition of claim 1 , wherein the silicate comprises an organic moiety attached to each of the four oxygen compounds of an orthosilicate.

11. The composition of claim 1 , wherein the silicate is tetraethylorthosilicate, tetramethylorthosilicate, tetrapropylorthosilicate, or tetrabutylorthosilicate.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 20, 2026
From: ORBIS HEALTH SOLUTIONS, LLC
To: ELIOS HOLDINGS, LLC
Reel/Frame 074417/0948 →
Continuity (5)
Division 16227468 · Dec 20, 2018
Division 15123479
Provisional Application 61948503 · Mar 5, 2014
Provisional Application 62060124 · Oct 6, 2014
Related Publication 20200368172A1 · Nov 26, 2020